title: Neonatal hyperbilirubinaemia: time for Italian recommendations?
abstract: The introduction of effective therapies for hyperbilirubinemia might have led to a general overconfidence among neonatal healthcare providers. National guidelines have been issued in many countries though they hardly stand the challenge of evidence-based medicine. A comparative appraisal shows significant discrepancies among different documents. As new, compelling evidence sheds a different light on bilirubin toxicity, this heterogeneity that borders confusion should be solved by implementing both clinical and basic research on the complex issue of neonatal hyperbilirubinemia.
authors.affiliation: Department of Pediatrics, Università Federico II, Naples, Italy. raimondi@unina.it
authors.forename: Francesco
authors.initials: F
authors.lastname: Raimondi
authors.forename: Carlo
authors.initials: C
authors.lastname: Dani
authors.forename: Costantino
authors.initials: C
authors.lastname: Romagnoli
authors.forename: Teresa
authors.initials: T
authors.lastname: Ferrara
authors.forename: Angela Carla
authors.initials: AC
authors.lastname: Borrelli
authors.forename: Letizia
authors.initials: L
authors.lastname: Capasso
mesh_terms: D019317:Evidence-Based Medicine; D006801:Humans; D051556:Hyperbilirubinemia, Neonatal / Q000628:therapy*; D007231:Infant, Newborn; D007558:Italy; D009359:Neonatology / Q000331:legislation & jurisprudence* / Q000379:methods; D017410:Practice Guidelines as Topic; D013997:Time Factors